Dinoprostone

Prostaglandin Analog — GENITO URINARY SYSTEM AND SEX HORMONES

Key facts

Dinoprostone is an ofp drug in the Prostaglandin Analog class catalogued in DrugCentral. It was first approved by the FDA in 1977. DrugCentral lists 25 molecular targets, including PTGER4, PTGER3 and Ptger3. Recorded indications include Cervical ripening procedure, Hydatidiform mole, benign, Incomplete miscarriage and Induction of labor.

• Approval status: ofp (first approved 1977 by the FDA).
• Drug class: Prostaglandin Analog.
• Molecular targets: PTGER4, PTGER3, Ptger3 and PTGER2 (25 listed in DrugCentral).
• Indications: Cervical ripening procedure, Hydatidiform mole, benign, Incomplete miscarriage, Induction of labor and Pregnancy with abortive outcome.
• ATC code: G02AD02 (Prostaglandins).
• Molecular formula: C20H32O5; molecular weight 352.47 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (5)

• Cervical ripening procedure
• Hydatidiform mole, benign
• Incomplete miscarriage
• Induction of labor
• Pregnancy with abortive outcome

Contraindications (29)

• Abnormal uterine bleeding unrelated to menstrual cycle
• Anemia
• Asthma
• Deliveries by cesarean
• Diabetes mellitus
• Disease of liver
• Disorder of cardiovascular system
• Disorder of lung
• Disproportion between fetus and pelvis
• Disseminated intravascular coagulation
• Endocervical Lesions
• Female genital tract infection
• Fetal distress
• Genital herpes simplex
• Glaucoma
• Grand multipara
• Gynecological Surgery
• Hypertensive disorder
• Inflammation of cervix
• Kidney disease
• Low blood pressure
• Multiple pregnancy
• Ocular hypertension
• Placenta previa
• Seizure disorder
• Spontaneous rupture of membranes
• Stenosis of cervix
• Uterine Hypertonic Patterns
• Uterine leiomyoma

Mechanism & targets

• Established pharmacologic class: Prostaglandin Analog

Molecular targets (25)

Target	Gene	Action	Activity
Prostaglandin E2 receptor EP4 subtype	PTGER4	agonist	Ki 9.77
Prostaglandin E2 receptor EP3 subtype	PTGER3	agonist	Ki 9.48
Prostaglandin E2 receptor EP3 subtype	Ptger3	agonist	EC50 9.39
Prostaglandin E2 receptor EP2 subtype	PTGER2	agonist	Ki 8.77
Prostaglandin E2 receptor EP4 subtype	Ptger4	unknown	IC50 8.68
Prostaglandin E2 receptor EP4 subtype	Ptger4	unknown	Ki 8.51
Prostaglandin E2 receptor EP3 subtype	Ptger3	unknown	Ki 8.30
Prostaglandin E2 receptor EP2 subtype	Ptger2	unknown	IC50 8.28
Prostaglandin E2 receptor EP1 subtype	Ptger1	unknown	Ki 8.22
Prostaglandin E2 receptor EP1 subtype	PTGER1	agonist	Ki 8.04
Prostaglandin E2 receptor EP1 subtype	Ptger1	agonist	Ki 7.70
Prostaglandin E2 receptor EP2 subtype	Ptger2	unknown	Ki 7.66
Prostaglandin D2 receptor	PTGDR	agonist	Ki 7.00
Prostaglandin F2-alpha receptor	Ptgfr	agonist	Ki 7.00
Prostaglandin F2-alpha receptor	PTGFR	agonist	Ki 6.90
Prostacyclin receptor	PTGIR	unknown	IC50 6.59
Cation channel sperm-associated protein 2	CATSPER2	activator	EC50 6.30
Cation channel sperm-associated protein 4	CATSPER4	activator	EC50 6.30
Cation channel sperm-associated protein 3	CATSPER3	activator	EC50 6.30
Cation channel sperm-associated protein 1	CATSPER1	activator	EC50 6.30

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2020-01-23	PMDA	—	Ferring Pharmaceuticals Co., Ltd.
1977-08-23	FDA	—	PHARMACIA AND UPJOHN

ATC classification

ATC code	Therapeutic hierarchy
G02AD02	GENITO URINARY SYSTEM AND SEX HORMONES › OTHER GYNECOLOGICALS › UTEROTONICS › Prostaglandins

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Uterine hyperstimulation	527.0
Foetal exposure during pregnancy	327.4
Premature separation of placenta	297.7
Foetal heart rate deceleration abnormality	285.6
Uterine tachysystole	276.4
Uterine hypertonus	271.8
Postpartum haemorrhage	250.0
Uterine rupture	230.2
Exposure during pregnancy	218.7
Neonatal asphyxia	187.5
Small for dates baby	184.1
Foetal exposure during delivery	161.1

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Dinoprostone is on its molecule page.

• Molecular formula: C₂₀H₃₂O₅
• Molecular weight: 352.47 g/mol
• CAS number: —
• InChIKey: XEYBRNLFEZDVAW-ARSRFYASSA-N
• PubChem CID: 5280360

CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Dinoprostone used for?

DrugCentral lists the following indications for Dinoprostone: Cervical ripening procedure, Hydatidiform mole, benign, Incomplete miscarriage, Induction of labor and Pregnancy with abortive outcome.

How does Dinoprostone work?

Its molecular targets in DrugCentral include PTGER4 (agonist), PTGER3 (agonist), Ptger3 (agonist) and PTGER2 (agonist).

When was Dinoprostone first approved?

Dinoprostone was first approved by the FDA in 1977.

What drug class does Dinoprostone belong to?

Dinoprostone is in the Prostaglandin Analog class.

What is the chemical formula of Dinoprostone?

Dinoprostone has the molecular formula C20H32O5 and a molecular weight of 352.47 g/mol.

Sources

• DrugCentral drug card 913 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL548 — compound record and bioactivity
• PubChem CID 5280360 — chemical identifiers
• DrugBank DB00917 — drug record
• FDA UNII K7Q1JQR04M — substance identity
• DailyMed: FDA labels for Dinoprostone — current prescribing information (label search)
• UniProt P35408 (PTGER4) — target protein
• UniProt P43115 (PTGER3) — target protein
• UniProt P43116 (PTGER2) — target protein
• UniProt P34995 (PTGER1) — target protein
• UniProt Q13258 (PTGDR) — target protein
• UniProt P43088 (PTGFR) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.